Skip Navigation LinksHome > August 2007 - Volume 2 - Issue 8 > Randomized multicenter german trial of surgery plus radiothe...
Journal of Thoracic Oncology:
doi: 10.1097/01.JTO.0000283095.94217.eb
Proffered Paper Abstracts: Session A1: Combined Modality Therapy in NSCLC I, Monday, September 3: Combined Modality Therapy in NSCLC I, Mon, 13:45 - 15:30

Randomized multicenter german trial of surgery plus radiotherapy versus tri-modality treatment of operable stage IIIA NSCLC - long-term follow-up results: A1-06

Eberhardt, Wilfried E.1; Korfee, Sönke1; Pöttgen, Christoph2; Wagner, Horst3; Gauler, Thomas1; Passlick, Bernward4; Stamatis, Georgios5; von Pawel, Joachim3; Budach, Volker6; Wilke, Hansjochen7; Stuschke, Martin2

Free Access
Article Outline
Collapse Box

Author Information

1 Dept. of Internal Medicine (Cancer Res.), West German Cancer Centre, University Hospital of the University of Duisburg-Essen, Essen, Germany 2 Dept. of Radiation Therapy, West German Cancer Centre, Essen, Germany 3 Asklepios Klinik Gauting, Gauting, Germany 4 Clinics for Thoracic Surgery, University Hopital, Freiburg, Germany 5 Dept. of Thoracic Endoscopy and Thoracic Surgery, Ruhrlandklinik Essen-Heidhausen, Essen, Germany 6 Clinic for Radiation Oncology, Charite Campus-Mitte, Berlin, Germany 7 Kliniken Essen-Mitte; Huyssen-Stiftung, Essen, Germany

Back to Top | Article Outline


1994, selected patients(pts) early stage IIIA-NSCLC (operable, 1-2 LN involved at mediastinoscopy, no clinical N2, no bulky/extranodal disease) were taken to upfront surgery(S) at centers in Europe/North America. We compared this approach to aggressive tri-modality therapy - induction chemotherapy(CTx), preoperative radiochemotherapy(RTx/CTx) and definitive S - in a multicenter randomized GERMAN KREBSHILFE trial (full trials grant).

Back to Top | Article Outline

Patients and Methods:

operable IIIA pts (criteria above, mediastinoscopy, central T3N0-1, WHO 0,1) stratified (TN-group, center) and randomized: arm A - S and postoperative RTx (50-60 Gy); arm B - induction CTx (3 x cisplatin(P) 60 mg/m2 d 1+7/etoposide(E) 150 mg/m2 d 3,4,5) + concurrent RTx/CTx (45 Gy; 1.5 Gy bid; 1 x P 50 mg/m2 d 2 + 9, E 100 mg/m2 d 4,5,6) + S (+ prophylactic cranial irradiation (PCI) - 15 x 2 Gy = 30 Gy in 3 wks) (preliminary data: Eberhardt et al, Lung Cancer 2003;41:S63(O-213), Suppl 2).

Back to Top | Article Outline


11/94 to 7/01 112 pts randomized. 6 pts (3/arm) not eligible (misstaging, pts refusal, early progression prior any study therapy). 106 pts eligible for complete analysis 3/2007: Pts characteristics M 90 F 16; age median (med) 59 (37-71); SCC 55 adeno-ca 35 LCC 16; A: n = 51 pts T3N0-1 3 T1-2N2 38 T3N2 10; B: n = 55 pts T3N0-1 3 T1-2N2 45 T3N2 7. A: S 50/50 probatory thoracotomy (PT) 5/50 R1/2 10/50 complete resection (R0) 35/50; B: S 39/54 PT 1/54 R1/2 6/54 R0 32/54; peri- and postoperative morbidity/mortality not significantly different between A/B (rate of early postoperative deaths, infections, stump insufficiencies, bleeding, embolisms, postop duration of hospitalization, time on postop respirator, time on ICU). Strong trend for more limited surgical resections following induction: number of pneumonectomies: A 22,B 11. Although terminated early due to slow accrual/emerging data for adjuvant CTx(IALT), the survival(surv) results as follows: median(med) overall surv: A 15 mo vs B 29 mo (p = 0.15 Wilcoxon W); med event-free surv: 9 mo vs 15 mo (p = 0.12 W); med disease specific(spec) surv 10 mo vs 18 mo ( p = 0.026 W). 5-year overall surv 18% vs 16%; event-free surv: 20% vs 24%; disease spec surv 23% vs 24%. Beyond 3 yrs from randomization intercurrent events (co-morbidities) and second cancers predominant reason for deaths. Med surv of pts still alive 3/07: 94 mo(n = 14,73+-149+).

Back to Top | Article Outline


This tri-modality protocol was feasible/safe in the multicenter setting. S following complex bi-modality induction did not show increased morbidity/mortality. Strong trend towards lung-sparing surgery in the arm with preoperative complex induction (down-staging? organ-sparing effect?). Results of this trial mandate rate of less extensive S interventions (eg. lobectomies) as further important endpoint to be added within clinical trials of comparable pts populations (significant risk for pneumonectomy at thoracotomy). Although surv data favoured tri-modality in the first four yrs - overall no of pts randomized does not allow valid conclusions concerning this endpoint. Currently, data on brain-relapse -free surv are analyzed with different policy for PCI in both arms (PCI vs no PCI).

Copyright © 2007 by the European Lung Cancer Conference and the International Association for the Study of Lung Cancer.


Article Tools


Other Ways to Connect



Visit on your smartphone. Scan this code (QR reader app required) with your phone and be taken directly to the site.

 For additional oncology content, visit LWW Oncology Journals on Facebook.